No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CRDF241220C3500
- 0.55
- +0.40+266.67%
15min DelayClose Dec 13 16:00 ET
0.80High0.55Low
0.80Open0.15Pre Close5 Volume123 Open Interest3.50Strike Price325.00Turnover197.27%IV3.32%PremiumDec 20, 2024Expiry Date0.42Intrinsic Value100Multiplier6DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type0.7171Delta0.3378Gamma6.27Leverage Ratio-0.0289Theta0.0004Rho4.50Eff Leverage0.0017Vega
Intraday
- 5D
- Daily
News
Cardiff Oncology Is Maintained at Overweight by Piper Sandler
Cardiff Oncology Analyst Ratings
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $10
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Cardiff Oncology Director Gary Pace Buys $940,199 in Stock
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study